Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Biobill,
Just another example of the far reaching tenicles of Fake News. It's everywhere, and they complained about Sen. McCarthy.
"Now you know the rest of the story", as a real journalist use to say.
The dumbing of America.
At the high of last week and near the high of the day. I Don't think so. JMO.
4 buys within 2 minute time frame for total of 1.929 million shares. Something going on today. Leak?
JL,
Different people have different levels of risk capabilities depending on personal makeup, or their situations regarding where they are in life.
I am still all in, but I have never had much skin in the game so that should mean very little to others.
Someone woke up on the wrong side of the bed.
Sts provides a lot of info and lets others comment. Nothing wrong with that. You could say the same thing about Google, but how much are our lives improved because of it. Nothing wrong with being provided more information.
Seems the low 4's are the target for now. Recovers quickly when it occasionally falls below that.
From Yahoo,
"Here's Why Amarin Corporation plc Surged 34% Higher in June
A closer look at results from a trial with Vascepa encouraged investors.
Cory Renauer (TMFang4apples) Jul 10, 2017 at 1:29PM
What happened
Shares of Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company that specializes in cardiovascular health, rose 34.3% in June according to data from S&P Global Market Intelligence. Positive clinical trial data concerning its lead drug, Vascepa, gave the market a reason to cheer.
So what
Amarin's Vascepa earned FDA approval in 2012 for the treatment of patients with circulating triglyceride levels above or equal to 500 mg/dl, a group that includes around 2% of the U.S. population. After a lengthy legal battle, the company also markets the fish oil derivative off-label to about 16% of the U.S. population with triglyceride levels in the 200 mg/dl to 499 mg/dl range despite treatment with statins.
Person in front of a series of upward sloping arrows.
IMAGE SOURCE: GETTY IMAGES.
Last month, the stock started jumping after Amarin presented a post hoc analysis of the Anchor trial. The company showed that Vascepa significantly lowered triglyceride levels among statin-treated women with type-2 diabetes. The data could help the company market the drug off-label to this group -- and significantly boost sales in the process.
Now what
An estimated one in three Americans is at risk of developing diabetes, and cardiovascular disease is one of the most common co-morbidities. Although high triglyceride levels are associated with increased risk of heart attack and stroke, there are lingering doubts about whether or not lowering them with Vascepa will actually reduce that risk.
Those doubts could lift or strengthen by the end of the year. In 2011, the company began an 8,175-patient trial to see if Vascepa treatment could significantly reduce the long-term risk of heart attack and other cardiovascular events. The company expects it will be able to present data from an interim analysis of the outcome study during the present quarter. The results of that data will dictate whether the stock will continue to soar or plummet........"
Will Amarin set the example for a more progressive FDA under the new Admin istration. I Don't think we will see the same FDA that treated Vascepa so harshly in the past. Tell tale clinks in the armour of the Bureaucracy of the FDA may start showing.
So many indications for Vascepa and such a great safety profile it could become the Aspirin of the 21 fst.century.
Exactly BB,
The recent action is probably due to day traders who know nothing about Amarin or Vascepa they just joined the ride for quick profit. This is what they do. Nothing at all wrong with it, it's just the way it is in the market. Next couple of trading days will be very interesting to see how many new core investors were actually attracted. We must be getting close to news regarding 80% issues or else this run would not have happened with this magnitude. Also, I like the term you used
"Flash". All the new technologies used today probably contribute to much of up, down action in today's markets. Great for day traders.
Interesting article written this past February.
https://www.google.com/amp/s/seekingalpha.com/amp/article/4041904-buy-amarin-reduce-trial-results
Patient lives will, and should trump all. A high RRR will end the trial at 80%. To impede an effective, safe drug from fully entering the market is just as wrong as knowingly approving a drug for profits that is harmful. As an example, self administration of dangerous opioids has been a disaster. Professionals in healthcare should have had the foresight to predict the horrorable outcome. Lives have been destroyed.
Today's action was by investors just along for the ride. They don't know very much about Vascepa they just wanted to ride the stock up and are jumping off with their profits. How it reacts from now will tell a lot about why this latest run up happened. We are getting very close to 80% interim announcement. If someone starts buying up shares now it will be because they feel very strongly about positive RI results and not just interested in short time profits.
We've seen too many rocket launches recently.
When I use to work for Western Electric, a Bell Sys. affiliate, there was a saying, " the 3 fastest forms of communication are telephone, telegraph, and tell a woman. The last is probably still true. Someone told a woman about Vascepa RI results and now the world knows. Hehe.
I bought shares in Micromet that the BB's were also invested. I paid 4.50 a share the company was bought for $11.00. I could wait weeks or months for my money, or sell for $10.96 to someone who was buying. I choose to sell. It turned out it was the BB's buying millions of shares between 10.90 and the upper 90's. It was a sure thing for them since they knew they would get 11.00. 5th
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
From yahoo ( options players expecting something to happen by July 21st )
Zacks
Zacks Equity Research
ZacksJune 28, 2017
Investors in Amarin Corporation plc AMRN need to pay close attention to the stock based on moves in the options market lately. That is because the July 21st, 2017, $6 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Amarin shares, but what is the fundamental picture for the company? Currently, Amarin is a Zacks Rank #4 (Sell) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 38% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while none have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 5 cents per shareto a loss of 6 cents in that period.
Given the way analysts feel about Amarin right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Raf,
Let's not forget that a consortium could afford to pay much more for Amarin. After 2-3 years in this stock I have a right to feel somewhat selfish about the matter.
JL,
Don't forget this one either,
"To the Moon Alice"
It will be interesting to see if the recent good news will be reflected in increased prescriptions. That along with the normal increases in scripts in the later quarters could lead to a greater rate of new investors. Let's hope so.
Good luck to all.
Must be very frustrating that the price doesn't drop enough for you to exit at a profit. Sorry I can't say good luck, that would be self defeating.
Raf,
Perhaps those on Vascepa will go on to live a healthy life style free of heart disease, arthritis, diabetes, and etc.
It's better to develope good drugs which don't just help with one indication while causing problems in another. I think the medical establishment will survive Vascepa and so will our economy which will sell more Dockers, vitamin pills, hiking boots, automobiles, and anything else old people buy, ole yeah let's not forget Viagra. The Baby Boomer generation has created many new markets, don't give up on us yet.
My wife, who is a nurse, told me that my fluid build up is caused by leaky vains. I said, "what is the technical term for that condition". She said, "leaky vains". I have learned over the years not to pursue and be persistent with her. So, I've leaky vains, perhaps I should look up a plumber in the yellow pages.lol. ( she didn't see the humor in that ). Thanks for the tips.
Sorry about your friend. You certainly did him a favor, as my wife did for me, I also had no chest pains, vitals looked a tad out of normal, but was short of breath which I attributed to my recurring pneumonia conditions. Turns out I had a 90% blockage and needed a stent.
Unfortunately I am. I have occasional swelling in my left ankle. I keep myself well hydrated though. I hate getting old, but unfortunately the only alternative isn't so good either.
Zum, Rose and all,
Thank you very much for your responses. To those I haven't named it is not that you are not appreciated, it's just that you all chatter so much at times it is difficult to find all the responses. Thank all of you very much.
Not as tired. I got a part time job which gets me up and moving. However, I am on about 10 different medications. Blood thinners such as Warfarin, blood pressure pills which I keep insisting that I do not need, statins, and etc. My blood pressure before the heart attack was 120/72. Even during my heart attack and my embolisms it was not high. I attribute that to my years of running. Since I have had my stent put in I am on about 10 different medications. Just seems to me that the prescriptions are made as standard procedures and not individual conditions. I am not happy about taking all these medications but recently since taking a sonogram test on my legs they found the remainance of a blood clot behind my knee and said I had leaky veins condition which is probably from all the rat poison ( Warfarin ) I have to take.
Just to add my experience to the debate. I was in good health until I was 66 years old, a former runner with great stats ( i.e. Blood pressure and etc.) I went to my GP and complained that I was feeling tired too often. He did a blood test and determined my testosterone levels were low and recommend I take androgel. I had never taken any medications, even aspirin and had always resisted doing so unless absolutely necessary. I had recently overcome my annual bout with pneumonia using antibiotics and when the symptoms reoccurred my doctor had determined that the pneumonia had returned. After climbing stairs and being out of breath I returned to my doctor who wanted to prescribe a different antibiotic, I suggested a cat scan to see what was going on, which I did. The doctor who did my scan told me I had multiple pulmonary embolisms, and I should go to the hospital next door, do not go home first, just tell them in the emergency room I was having breathing issues and show them the scan results with his diagnosis. I was in the hospital for a week. A year ago I had a heart attack, 90% blockage. I believe the root of my problems was the androgel since I've noticed that a lot of commercials are running stating such. When I ask anyone in the medical profession about the cause of my problems they make certain not to comment on the androgel
My point is that it is very important to thoroughly test medications before they enter the market, but it is also important to use some common sense about safety issues. A proven molecule such as those in fish oil, should not be subjected to the same scrutiny as andogel, for example. I can't see how androgel was ever approved without some type of corruption being involved, unfortunately that type of behavior will never be fully eliminated. Unless someone had a allergic reaction I have never heard of anyone dying from using fish oil. It's effects and safety have been known for thousands of years, so for the FDA to react to it in the manner it has for the past four years is just another form of corruption and professional bias IMO. Greed, money and influences, are the real root of the problems in the pharmaceutical industry. Just look at the mess that has been made by the approval of self medications of opioids for pain. It is a shameless national tragedy whose results should have been known well in advance but for the fact that billions of dollars of profits were involved.
Is the Options Market Predicting a Spike in Amarin Corporation (AMRN) Stock?
Zacks
Zacks Equity Research
ZacksMay 8, 2017
Investors in Amarin Corporation plc AMRN need to pay close attention to the stock based on moves in the options market lately. That is because the September 15th, 2017 $3.50 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Amarin Corporation shares, but what is the fundamental picture for the company? Currently, Amarin Corporation is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 40% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while one analyst has revised estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of six cents per share to a loss of seven cents in that period.
Given the way analysts feel about Amarin Corporation right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
----------
It's never easy.
Sound advice, thanks. I'll try harder to restrain myself, but what good is money if you are living in France, speaking metaphorically of course. I had to add that so I wouldn't get a failing grade on my comments.
A mind is a terrible thing to waste. What gibberish. Get off topic much?
Sorry Mrs. Clinton,
But you know exactly what I am talking about.
Call me disillusioned but I think the Snow Fakes that run Berkeley College in CA. are turning that institution into a banana republic type institution and to think that we are forced to provide our tax dollars for that type of brain washing.
I guess it is important that those concerned with making pharmaceutical decisions not be influenced by Fake News. This isn't a college campus, its the real world, Snowflakes.Hahaha.
You nailed it, Raf.
For a pre-arranged short attack it is not working very well. I actually believe the stock is showing strength under the circumstance and expect much buying very soon when concerned parties believe it bottoms out.
Many investors consider this a long time play and with news of the possibility of Trump care being approved by the house investors may feel that it opens the opportunity for Trump's tax cuts and the eventual large influx of cash into the business sector. Perhaps the investors see other more immediate opportunities opening up.
The lead in for the article is a little misleading. As far as I know it is only the Baker bros. who own Amarin shares. The other guys they mention may own shares in the other two companies, or they may have just used them as an example of investors to follow. Which ever, having an endorsement of the Baker bros, considering they specialize in health care, is still a very big deal. The BB's are not infallible, but they are right very much more than not. Getting the word out about Amarin and Vascepa to the investment community is what I find important. The more knowledge about the existence of our little company, the more research that will be done by the investment community regarding Vascepa by not only the institutional investors but also the mom and pop investors who have no Idea that we even exist.
3 Stocks the Smartest Investors Are Buying Right Now
These three stocks have attracted some of brightest investors in the world.
George Budwell, Rich Smith, And Matthew DiLallo (TMFGBudwell) Apr 7, 2017 at 10:24AM
Keeping tabs on the quarterly activity of elite billionaire investors like George Soros and David Tepper can be a good way to drum up worthwhile investing ideas. However, everyday investors should never buy a stock simply because a so-called super-investor added it to their portfolio.
After all, it's exceedingly difficult to decipher how individual buys might fit into the broader investment strategy of a billionaire investor that holds a wide array of positions. Moreover, even billionaires have been known to pick duds on occasion.
Keeping this theme in mind, our contributors noticed that some of the smartest investors have been grabbing shares of Amarin Corp. (NASDAQ:AMRN), Key Energy Services (NYSE:KEG), and Allergan (NYSE:AGN) in recent quarters. So, let's consider if these three stocks are sound investment ideas for regular folks, or potential landmines best avoided by everyday investors.
Chess.
IMAGE SOURCE: GETTY IMAGES.
This Irish biopharma is attracting the attention of some of the best investors
George Budwell (Amarin Corp.): Felix and Julian Baker are two of the best -- if not the best -- healthcare investors on the planet today. So, when their hedge fund, Baker Bros. Advisors, starts piling into a particular stock, it's usually worth the time to consider why.
The latest 13F filings, for instance, revealed that the Bakers' hedge fund purchased another 1.539 million shares of the small-cap biopharma Amarin Corp. in the fourth quarter of 2016. Perhaps most telling, the fund now owns roughly 8% of Amarin's outstanding shares.
What's attracting these top investors to Amarin? Amarin makes a highly refined FDA-approved fish oil pill known as Vascepa that's currently on the market for patients with severely elevated triglyceride levels. However, Amarin is hoping to broaden its label soon to include patients with only modestly high triglyceride levels. To do so, the company needs a positive data readout from the drug's ongoing cardiovascular outcomes trial, known as REDUCE-IT.
The key takeaway is that Vascepa has the potential to break into a market with approximately 75 million patients in the United States alone. If so, this drug could go on to generate megablockbuster sales, which would be a huge win for the company and its shareholders.
Of course, it's never a good idea to blindly follow any investor, regardless of their track record in a specific sector. Amarin's stock, after all, could implode if REDUCE-IT misses the mark.
---------------------------
Of course we already know this but it is nice to see someone get the word out,.......no?
Lol. Know what you mean but any enthusiasm is good enthusiasm. How many investor/analyst know how to write software code ( or even know what it is ) but suggested others invest in Microsoft.